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ABSTRACT
Objectives: The International Society for Pharmacoeconomics and Out-
comes Research (ISPOR) Health Science Policy Council recommended and
the ISPOR Board of Directors approved the formation of a Task Force to
critically examine the major issues related to Quality Improvement in
Cost-effectiveness Research (QICER). The Council’s primary recommen-
dation for this Task Force was that it should report on the quality of
cost-effectiveness research and make recommendations to facilitate the
improvement of pharmacoeconomics and health outcomes research and its
use in stimulating better health care and policy. Task force members were
knowledgeable and experienced in medicine, pharmacy, biostatistics,
health policy and health-care decision-making, biomedical knowledge
transfer, health economics, and pharmacoeconomics. They were drawn
from industry, academia, consulting organizations, and advisors to gov-
ernments and came from Japan, the Netherlands, Canada and the United
States.
Methods: Face-to-face meetings of the Task Force were held at ISPOR
North American and European meetings and teleconferences occurred
every few months. Literature reviews and surveys were conducted and the
ﬁrst preliminary ﬁndings presented at an open forum at the May 2008
ISPOR meeting in Toronto. The ﬁnal draft report was circulated to the
expert reviewer group and then to the entire membership for comment.
The draft report was posted on the ISPOR Web site in April 2009. All
formal comments received were posted to the association Web site and
presented for discussion at the Task Force forum during the ISPOR 14th
Annual International Meeting in May 2009. Comments and feedback
from the forums, reviewers and membership were considered in the ﬁnal
report. Once Task Force consensus was reached, the article was submitted
to Value in Health.
Conclusions: The QICER Task Force recommends that ISPOR implement
the following:
• With respect to CER guidelines, that ISPOR promote harmonization
of guidelines, allowing for differences in application, regional needs
and politics; evaluate available instruments or promote development
of a new one that will allow standardized quantiﬁcation of the
impact of CER guidelines on the quality of CER studies; report
periodically on those countries or regions that have developed
guidelines; periodically evaluate the quality of published studies
(those journals with CER guidances) or those submitted to decision-
making bodies (as public transparency increases).
• With respect to methodologies, that ISPOR promote publication of
methodological guidelines in more applied journals in more easily
understandable format to transfer knowledge to researchers who
need to apply more rigorous methods; promote full availability of
models in electronic format to combat space restrictions in hardcopy
publications; promote consistency of methodological review for all
CER studies; promote adoption of explicit best practices guidelines
among regulatory and reimbursement authorities; periodically
update all ISPOR Task Force reports; periodically review use of
ISPOR Task Force guidelines; periodically report on statistical and
methodological challenges in HE; evaluate periodically whether
ISPOR’s methodological guidelines lead to improved quality; and
support training and knowledge transfer of rigorous CER method-
ologies to researchers and health care decision-makers.
• With respect to publications, that ISPOR develop standard CER
guidances to which journals will be able to refer their authors and
their reviewers; lobby to establish these guidances within the Inter-
national Committee for Medical Journal Editors (ICMJE) Require-
ments to which most journals refer in their Author Instructions;
provide support in terms of additional reviewer expertise to those
journals lacking appropriate reviewers; periodically report on jour-
nals publishing CER research; periodically report on the quality of
CER publications; and support training and knowledge transfer of
the use of these guidelines to researchers and reviewers.
• With respect to evidence-based health-care decision-making, that
ISPOR recognize at its annual meetings those countries/agencies/
private companies/researchers using CER well, and those practitio-
ners and researchers supporting good patient use of CER in
decision-making; and promote public presentation of case studies of
applied use of CER concepts or guidelines.
Keywords: cost-effectiveness, guidelines, health economics, quality
improvement.
Background to theTask Force
The International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) Health Science Policy Council recommended
that the ISPOR Board of Directors establish a Task Force to
critically examine the major issues related to Quality Improve-
ment in Cost-effectiveness Research (QICER) in July 2005. The
Council’s primary recommendation for this new Task Force was
that it should report on the quality of cost-effectiveness research
and make recommendations to facilitate the improvement of
pharmacoeconomics and health outcomes research and its use in
stimulating better health care and policy. The ISPOR Board of
Directors approved creation of the Task Force in December
2005. An email was sent to all ISPOR members in March 2006
seeking candidates interested in serving on the leadership group
or the expert reviewer group. Task Force leadership and reviewer
groups were ﬁnalized by October 2006. Task Force members
were knowledgeable and experienced in medicine, pharmacy,
biostatistics, health policy and health care decision-making,
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biomedical knowledge transfer, health economics and pharma-
coeconomics. They were drawn from industry, academia, con-
sulting organizations, and advisors to governments and came
from Japan, The Netherlands, Canada and the United States.
Face-to-face meetings of the Task Force were held at ISPOR
North American and European meetings and teleconferences
occurred every few months. Literature reviews and surveys were
conducted and the ﬁrst preliminary ﬁndings presented at an open
forum at the May 2008 ISPOR meeting in Toronto. The ﬁnal
draft report was circulated to the expert reviewer group in March
2009 and then to the entire membership for comment in April
2009. The draft report was posted on the ISPOR web site in April
2009; 26 responses were received. All formal comments received
were posted to the ISPOR Web site and presented for discussion
at the Task Force forum during the ISPOR 14th Annual Interna-
tional Meeting in May 2009. Comments and feedback from the
forums, reviewers and membership were considered in the ﬁnal
report. Once Task Force consensus was reached, the article was
submitted to Value in Health.
Introduction
Quality assessment and continuous quality improvement has
long been recognized as a vital process in all societal systems and
organizations. In health care, critical review of interventions and
reports on the quality of outcomes can help correct deﬁciencies
and further advance efﬁciency and quality. Continuous quality
improvement is integral to our global efforts to improve the
economics and quality of life in all health care sectors and all
patient populations. There is an important role for ISPOR in
macro review and examination of quality and trends in pharma-
coeconomics, health care economics research, and their resulting
impact on global policies and practice.
Mission
The mission of the ISPOR Task Force on Quality Improvement
in Cost-effectiveness Research (QICER) is to generate periodic
quality reports and make recommendations to facilitate the
improvement of pharmacoeconomics and health outcomes
research, and its use in stimulating better health care and
policy. This will be accomplished through periodic systematic
reviews and surveys. The results and ﬁndings will be made
available to ISPOR membership for comments and published as
white papers and reports, including recommendations for
future ISPOR initiatives, educational programs, and member
services.
In this ﬁrst report, the task force has focused primarily on
cost-effectiveness research (CER). While broader topics in
health economics and outcomes research (HEOR), such as
patient reported outcomes, health-related quality of life, train-
ing, software, etc., are beyond the range of this ﬁrst report,
they are envisioned as targets for future work. The HEOR
scope was, however, considered in our discussion of journals to
capture a more holistic view of the current state of peer-
reviewed publication and to position CER within a broader
perspective.
As summarized in Figure 1, organizationally and individually,
we embrace patients, providers, researchers, regulators, and
payers to collectively advocate that scarce health care resources
are allocated wisely, fairly, and efﬁciently. These health sector
linkages are promoted through organizational services that facili-
tate education, communications, research, and international
cooperation. Continuous quality improvement efforts are vital
for improving activities and outcomes from international policies
to individual patient care. The outside ring in the diagram depicts
the classic phases for quality improvement that include: develop-
ing guidelines, designing guideline implementation, conducting
interventions, measuring impact, analyzing outcomes, and the
feedback for improved guidelines.
The Role of Guidelines in
Quality Improvement
What role do guidelines play in promoting the quality and
improvement of CER? It is usually assumed that the presence
of guidelines leads to quality improvement, assuming that
established guidelines increase credibility and usefulness by
deﬁning generally accepted standards and the requirements of
speciﬁc users. However, in this ﬁeld, there is not much evidence
to support or disprove this assumption. A number of studies
have evaluated the quality of research, but few have examined
the relationship between the presence of guidelines and the
quality of research. Two topics were examined: the availability
of HEOR guidelines and the impact of guidelines on the quality
of CER.
A few authors have reviewed available guidelines, comparing
and contrasting them [1–3], and other resources are also avail-
able at: http://www.ISPOR.org; http://www.biomedcom.org/en/
resources-BMC-databases.html. Most guidances have similar
content with minor variations, but some signiﬁcant differences
do exist among them, most generally because of their intended
purpose, the audience to be addressed, regional, cultural or
political variation, or author or sponsor preferences.
How can the impact of guidelines on CER quality be mea-
sured? Most journals neither have speciﬁc guidelines or re-
quirements for HEOR (see further discussion), nor do authors
normally reveal which guidelines, if any, they observe. So
despite easy accessibility of published articles, their quality,
and the improvement of their quality, is not easily linked to
speciﬁc guidelines. Those who measure the quality of HEOR
publications [1,4–8] choose their own quality measures from
those guidelines currently available and generally accepted
standards.
Several formulary evaluation bodies (such as NICE in the UK
[9], Canadian Agency for Drugs and Technology in Health
(CADTH) in Canada [10], and PBS in Australia [11–13]) have
developed speciﬁc guidances and requirements for HEOR studies
submitted, but these studies are often not publicly available for
evaluation in the short term. Some of these bodies have per-
formed, or allowed, quality evaluation of studies submitted to
them, which have been presented publicly [14] or published
[15,16]. These often use small samples, are qualitative, and more
importantly, not easily comparable across jurisdictions.
The Evolution of Guidelines
Guideline development began in Australia in 1992, followed
closely by Canada and a few academic groups in the United
States [17–19]. Their form has tended to reﬂect their purpose,
e.g., those intended for reimbursement decision-making tend
to be more prescriptive, while those with more academic pur-
poses more descriptive (discussion of the appropriateness of
each will be left to a future report focused speciﬁcally on
guidelines).
Over the last decade, many countries have produced their
own guidances and others are in development. There are cur-
rently about 39 CER guidances from 34 countries (with multiples
from some countries). These have been produced by government
bodies, by academic groups, and health-care insurers, and fre-
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quently as collaborations among all three groups. Over half of
these were prepared as part of formulary submission guidances
or requirements. Table 1 summarizes those guidelines of which
we are currently aware. The task force welcomes all feedback on
publicly available new guidelines or updates not included here.
Measuring and Improving Guideline Quality
No instrument has been found that permits quantitative mea-
surement of guideline quality, or comparison of guidelines. What
publicly available information there is has been rather qualita-
tive; for example, in the early days of guideline development,
Regence BlueShield found that guidelines were practical from a
logistics perspective, improving the relevance and timeliness of
information available for decision-makers [54].
Although guidelines have not been quantitatively evaluated,
there are some studies published evaluating the quality of
studies submitted to the guideline-producing bodies. In one of
these, Hill et al. evaluated 326 Australian studies and found
signiﬁcant issues in the interpretation of guidelines and in the
conduct of studies [16]. In another, Colmenero et al. analyzed
53 economic studies submitted to US-managed care organiza-
tions and found low levels of compliance with accepted stan-
dards of CER research [55]. One pilot study did measure the
relationship between speciﬁc guidelines and the quality of
studies submitted [56]. Unfortunately, among published studies
of the quality of studies, the measures used are not easily
comparable.
If the impact of guidelines on quality of studies, and improve-
ment of quality, is to be assessed rigorously, a tool is required that
is quantiﬁable, anchored to guidelines, and to generally accepted
practices, and comparable across guidelines, studies, and time.
There does not appear to be an instrument that yet ﬁts this
objective, but possibly, one might be developed incorporating the
most relevant aspects of existing tools. Some already in use that
might be considered include: 1) Neumann et al. measured the
quality of economic analyses in several studies over the last
decade [5,6]; 2) Chiou et al. developed a grading system to
measure the value and quality of CER analyses using the QHES
instrument [1]; and 3) Goetghebeur et al. evaluated quality of 10
submissions to the Canadian Common Drug Review, assessing
the studies submitted with respect to the CADTH requirements
[56,57].
Future Work
Based on this preliminary review, there are a number of promis-
ing steps that could be taken with regard to guidelines as instru-
ments in measuring and improving quality in CER:
1. Perform a formal evaluation of currently available instru-
ments that might be used to quantify and compare the value
of CER guidelines. If none are found that meet this need,
adapt, develop, or promote the development of one.
2. Once an instrument is available to assess guideline quality,
promote the harmonization of guidelines, allowing for dif-
ferences in application, regional needs, and politics.
Figure 1 ISPOR vision and continuous quality improvement.
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3. Concurrently, evaluate available instruments or promote
development of one to quantify the impact of CER guide-
lines on the quality of CER studies. The outcomes of such
an instrument should allow comparison across guidelines as
well as comparison over time, to allow rigorous longitudi-
nal evaluation of quality improvement.
4. Encourage adoption of and adherence to CER guidelines
through training and knowledge transfer.
Statistics and Science
Introduction
There are a number of statistical issues in CER, which could
beneﬁt from standard approaches to address these issues. Rec-
ommendations for improving the statistical methods applied in
the cost-effectiveness literature are presented. The statistical
issues and their solutions are discussed separately for the two
most common approaches to cost-effectiveness analyses, namely,
clinical trial-based economic evaluations and decision modeling-
based studies. Economic evaluations based on registry and
administrative data sets have started gaining popularity in recent
years, and several of the issues discussed herein also apply to such
analyses. However, a comprehensive discussion of all the statis-
tical issues and approaches to address such issues that arise in
analyses of nonrandomized observational data are beyond the
scope of this ﬁrst article.
Statistical Issues in Clinical Trial–Based
Economic Evaluations
A critical source of the evidence on costs and cost-effectiveness of
new medical treatments comes from analyses of patient-level
data on cost and effect collected as part of randomized clinical
trials. The number of clinical trial–based economic evaluations
has increased considerably over the last decade. In the same time
frame, the ﬁeld has matured substantially, including the advance-
ment of, and a growing consensus about, appropriate statistical
methods for analysis of costs and cost-effectiveness alongside
clinical trials [58]. Systematic reviews suggest that published
studies on clinical trial based economic evaluations have begun
to use some of these new statistical techniques [59,60]. Never-
theless, there are still a substantial number of studies using sta-
tistical methods of poor quality. In addition, there still remain
areas needing further research.
Joint comparison of costs and effects and estimation of sampling
uncertainty. A joint comparison of costs and effects using the
incremental cost-effectiveness ratio (ICER) or the incremental
net monetary (health) beneﬁt is a useful decision tool to help
determine whether the new therapy offers good value relative to
the alternative. The use of this tool is particularly important
when there is a trade-off between costs and effects; that is, one
therapy is both signiﬁcantly more effective and more costly
compared with the other therapy. If there is no trade-off
between costs and effects, that is, when one therapy is signiﬁ-
cantly more effective and less costly when compared with the
other therapy, this decision tool may not be necessary because
that therapy is unambiguously dominant over its alternative. A
third possibility occurs when the two treatments have the same
effect. In this case, some authors have interpreted textbooks and
guidelines on health economic evaluations to suggest that a cost
minimization approach is sufﬁcient (i.e., the lowest cost treat-
ment is the treatment of choice) and there is no need to perform
a joint comparison of costs and effects [61–64]. Nevertheless, as
our understanding of sampling uncertainty for the comparison
of costs and effects has grown, the cases where this interpreta-
tion is appropriate is not as common as previously thought.
Because cost-effectiveness ratios and net monetary beneﬁt esti-
mated from trial data are the result of samples drawn from the
population, one should report the uncertainty in this outcome
that derives from such sampling. Identiﬁcation of methods such
as conﬁdence intervals for cost-effectiveness ratios [65–68],
acceptability curves [69], and conﬁdence intervals for net mon-
etary beneﬁt [70] for the measurement of this uncertainty have
been important methodologic developments in the economic
evaluation of medical therapies [71,72]. As a result of uncer-
tainty, the cost-minimization approach has been shown to be
rarely appropriate as a method of analysis and the need for a
joint comparison still remains under most circumstances [73].
Alternatively, observing no signiﬁcant difference in costs and
effects alone need not rule out that one can still be conﬁdent
that one of the two therapies is good value because it is possible
to have more conﬁdence in the combined outcome of differences
in costs and effects than in either outcome alone. In these cases,
one should jointly compare costs and effects, and one should
report on their sampling uncertainty.
Analysis of cost data. For all economic analysis calculations,
costs and cost differences between treatment groups should be
expressed by the use of the arithmetic mean, and not medians,
because this summary measure permits a budgetary assessment
of treatment (N ¥ arithmetic mean = total cost) and is the statis-
tic of interest for health-care policy decisions [58]. Because of the
often highly skewed distribution of cost data, the normality
assumption underlying the parametric t test is often called into
question and standard nonparametric tests (e.g., Mann-Whitney
U-test or Wilcoxon rank-sum test), or parametric tests on nor-
malizing transformations (e.g., log transformation) are often
Table 1 Countries, regions, or groups with publicly available health
economic research guidances
Source
Australia [11–13]
The Baltics (Latvia, Estonia & Lithuania) [20]
Austria [21]
Belgium [22]
Brazil [23]
Canada (CADTH, Ontario) [24]
China [25]
Finland [26]
France [27,28]
Germany [29]
Hungary [30]
Ireland [31]
Israel [32]
Italy [33]
Mexico [34]
The Netherlands [35]
New Zealand [36]
Norway [37]
Poland [38,39]
Portugal [40]
Russia [41]
Scotland [42]
Singapore [43]
Slovak Republic [44]
South Korea [45]
Spain [46]
Sweden [47]
Switzerland [48]
Taiwan [43]
UK (England and Wales) [49]
USA (task force, Gold Panel,AMCP,WellPoint) [50–53]
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used as a substitute. Yet these popular alternatives are not appro-
priate for drawing statistical inferences on differences in arith-
metic mean costs [74–76]. For example, when one uses a t test to
evaluate the log of costs, the resulting P-value has direct appli-
cability to the difference in the log of costs and to the difference
in the geometric mean of costs. It may or may not be directly
applicable to the arithmetic mean costs. A Mann-Whitney U-test
tests differences in the median of costs. Thus, statistical infer-
ences about these other statistics may not be representative of
inferences about the differences in arithmetic mean, which is the
statistic of interest. If one does not want to adopt a parametric t
test to directly test for differences in arithmetic mean costs, one
can compare the arithmetic means by using a nonparametric
bootstrap. This procedure has the added advantage of avoiding a
parametric assumption about the distribution of costs. As a
result, the nonparametric bootstrap has increasingly been recom-
mended either as a check on the robustness of standard paramet-
ric t tests, or as the primary statistical test for making inferences
about arithmetic means for moderately sized samples of highly
skewed cost data [76–78].
Many clinical trial-based economic evaluations are limited to
univariate analyses of costs. Even if treatment is assigned in a
randomized setting, there are advantages to using multivariable
techniques to analyze costs. Multivariable analysis of costs may
be superior to univariate analysis because it improves the power
for tests of differences between groups (by explaining variation
due to other causes). It also facilitates subgroup analyses for
cost-effectiveness, for example, more and less severe; different
countries/centers, etc. Finally, it accounts for potentially large
and inﬂuential variations in economic conditions and practice
patterns by provider, center, or country that may not be balanced
by randomization. Adoption of multivariable analysis does not,
however, avoid the issues that arise in the univariate analysis of
cost. For example, regressions on the logarithmic transformation
of costs were previously considered an ideal remedy to the vio-
lation of the assumption of normally distributed error term that
underlies ordinary least squares regression. Nevertheless, as the
shortcomings of multiple regression models of log transformed
costs became more widely publicized [75], the use of the gener-
alized linear models have become the more acceptable alternative
[79–81].
Handling of censored cost data. Incomplete or censored cost
data occur in most randomized trials that follow participants for
clinically meaningful lengths of time; yet they are often not
addressed in the analysis. The ISPOR RCT-CEA taskforce rec-
ommended that “ignoring small amounts of missing data is
acceptable if a reasonable case can be made that doing so is
unlikely to bias treatment group comparisons [58]. However, no
clear guidance exists for how much censoring is too much.
Hence, whether or not cost data were incomplete, the amount of
incomplete data and the statistical method adopted to address
any problems posed by incomplete data should routinely be
reported in trial-based analyses [58] Many studies in the litera-
ture have adopted naïve approaches wherein censored observa-
tions are either excluded from analysis (i.e., complete-case
analysis) or included as though they were complete observations,
(i.e., full sample analysis). In the ﬁrst naïve approach, only the
uncensored cases are used in the estimation of mean cost and this
method is biased toward the costs of the patients with shorter
survival times because patients with larger survival times are
more likely to be censored [82,83] Also, completely discarding
patients with censored data can lead to the loss of information
and statistical power, which can be problematic if the percentage
of censored cases is high. The second naive approach that uses all
cases without differentiating between censored and uncensored
observations is always biased downward, because the costs
incurred after censoring times are not accounted for [83].
Although there exists a mix of approaches to impute the cost
data, recent statistical interest in addressing censored cost data
has led to the proposal of several methods of estimation that
explicitly account for incomplete cost data due to loss-to-
follow-up [82,84–95] It is well established that these methods are
prone to less bias and return a better estimate of sampling vari-
ance than other naive estimation methods [82,83,87,89,96–98].
Sample size and power. Prior to the development of methods for
assessing sampling uncertainty for the joint comparison of cost
and effect, health economists commonly attempted to estimate
sample size based on the larger of the sample sizes needed for
estimating prespeciﬁed cost and effect differences—i.e., what
sample size was required to identify a $1000 difference in costs,
and what was required to identify a 10% reduction in mortality.
With the development of methods for assessing uncertainty,
sample size calculations should now be based on the sample size
needed to rule out that the net monetary beneﬁts of the interven-
tion are less than zero [99–102]. Often economic evaluations are
piggy-backed on clinical trials with a prespeciﬁed sample size. In
such instances, researchers should estimate and report the power
available to rule out cost-effectiveness ratios that exceed the
maximum willingness to pay.
Evaluating transferability (generalizability) of trial results. Mul-
tinational clinical trials are the norm for the evaluation of new
medical therapies. However, the presence of between-country
heterogeneity in trials has led to a growing concern that the
pooled or average economic results from multinational trials may
not be reﬂective of the results that would be observed in indi-
vidual countries that participated in the trial [103]. Common
sources for concern about the representativeness of data from
multinational trials include transnational differences in
morbidity/mortality patterns; practice patterns (i.e., medical
service use); and absolute and relative prices for medical service
use (i.e., price weights). The use of trial-wide clinical results,
trial-wide medical service use, and price weights from a single
country has been one of the commonly proposed, potentially
inadequate solutions to the problem of transferability (e.g., to
tailor the results to the UK, simply use UK price weights, and
conduct the analysis as if all participants were treated in the UK).
A second potentially inadequate solution has been to use trial-
wide clinical results, and country-speciﬁc medical service use and
price weights. Both approaches have the failing that they ignore
the fact that clinical and economic outcomes may inﬂuence one
another. That is, differences in cost may affect practice patterns,
which in turn may affect outcome; differences in practice pattern
may affect outcome, which in turn may affect cost. The ISPOR
Good Research Practices task force on Economic Data Transfer-
ability has recently recommended good research practices for
dealing with aspects of transferability including three proposed
statistical methods that use patient-level data to address
transferability: detection of heterogeneity [104,105], ﬁxed
effects models [106,107] and multilevel, or hierarchical models
[108–115].
Decision Models
The estimation of the full economic effects of health technologies
generally requires the extrapolation of clinical trial evidence
beyond the follow-up period through the use of decision model-
ing techniques to synthesize data from various sources. The aim
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of the modeling study is to aid decision-makers in making deci-
sions under uncertainty. Obviously, the results of modeling
studies will only be helpful to decision-makers if the study is
performed according to current standards. While the quality of
cost-effectiveness analyses has improved over time, still current
studies do not address all issues appropriately [5,113]. It is clear
that guidance is important for those performing modeling
studies. In several countries, authorities have formulated guide-
lines, and ISPOR has also published guidelines through the task
force on Good Research Practice in Modeling Studies [116].
Some of the most important issues where quality might be
improved, and some new methodological topics that have
emerged in the past few years, are discussed.
Methods for evidence synthesis. The ISPOR task force on Good
Research Practice in Modeling Studies suggested in their report
that systematic review should be conducted on key model inputs.
There are various ways of synthesizing the evidence found in
various studies (e.g., ﬁxed or random effects meta-analysis, either
frequentist or Bayesian), but there is not one optimal method of
synthesizing data currently available [117], and the typical meta-
analyses cannot straightforwardly be applied to synthesize data
for cost-effectiveness models.
One reason is that meta-analysis has been developed to
combine quantitative results of several similar studies into a
pooled estimate of the treatment effect (e.g., odds ratio, relative
risk, difference in change from baseline). It uses the magnitude of
the treatment effect and its uncertainty from each individual
study to produce a weighted mean of the treatment effect
[118,119]. However, in modeling studies, the parameter to be
estimated is not only a treatment effect like the odds ratio of
having an event. Typically, models contain parameters like tran-
sition probabilities between disease states, event probabilities,
rate ratios of treatment effects, quality of life or utility values,
and costs. These parameters have different distributions which
need to be combined. Moreover, the comparator needs to be
modeled too, meaning that we are dealing with more heteroge-
neity than usually remains after the variance in treatment effect
has been corrected for the variance in comparator-effect.
Second, meta-analyses have traditionally been performed on
studies that compare the same intervention with the same com-
parator. However, comprehensive decision analytic models aim
to identify the most cost-effective treatment among the entire
spectrum of all relevant treatment options. This issue may be
dealt with through so-called mixed treatment comparisons,
which combine multiple different pairwise comparisons across a
range of different interventions [120–123]. In mixed treatment
comparisons, the relative effect of a treatment compared to a
range of alternatives is estimated by including indirect compari-
sons of two interventions through a common comparator. Evi-
dence from direct and indirect comparisons are analyzed
simultaneously, which allows estimates of treatment effects in the
absence of head-to-head comparisons. Such mixed treatment
comparisons are inevitable in modeling cost-effectiveness.
The fact that the choice between ﬁxed and random effects
model and between a Bayesian and a frequentist approach can
have a large impact on the outcome of the model underlines the
need for complete transparency in the reporting of a modeling
study.
Probabilistic sensitivity analysis. Sensitivity analysis should
always be an integral part of a modeling study: input parameters
of the model are varied to see if and how the outcome changes.
For a long time, the common type of sensitivity analysis was
a deterministic one-way or multi-way analysis, in which one or
more (usually not more than three) parameters are varied
between certain limits. In the last few years, however, more and
more studies include a probabilistic sensitivity analysis, in which
(ideally) all input variables are varied simultaneously, according
to probability distributions [124]. Such an analysis presents
information on all possible outcomes, as well as on the likelihood
of these outcomes.
In their report, the ISPOR task force on Good Research
Practice in Modeling Studies stresses the need to include a sen-
sitivity analysis as part of the modeling study. While those task
force guidelines mentions that deterministic and probabilistic
analyses are equally appropriate, other guidelines such as the UK
and Dutch guidelines strongly prefer a probabilistic sensitivity
analysis as a way to correctly represent parameter uncertainty.
However, there are still good reasons to also include determinis-
tic sensitivity analysis in a modeling study, such as to account for
other types of uncertainty such as uncertainty relating to the
structure and assumption of decision models [125]. Series of
sensitivity analyses may be done to look at the consequence of
changing different assumptions and scenarios in a model.
Recently, however, an article was published exploring the option
of explicitly incorporating structural uncertainties into the model
[126].
Value-of-information. In the last few years, much attention has
been given to Value-of-Information (VOI) analysis [127,128].
This type of analysis addresses the question of what the value is
of collecting additional information to eliminate or reduce uncer-
tainty, since making the wrong decision comes with a cost that is
equal to the beneﬁts forgone because of the wrong decision.
These expected costs of uncertainty can be determined by 1) the
probability that a decision based on the current ICER is wrong;
and 2) the size of the opportunity loss if the wrong decision is
made.
The ﬁrst step in a VOI analysis is the estimation of the
expected value of perfect information, which is the maximum
amount the decision-maker should be willing to pay to eliminate
all uncertainty in the decision. The next step is to calculate the
expected value of partial perfect information, which is the
maximum amount the decision-maker should be willing to pay to
eliminate all uncertainty on one parameter or subset of param-
eters [129], Based on the latter analyses, priorities may be set for
further research. The ﬁnal part of the VOI is to calculate the
expected value of sampling information, which is the maximum
amount the decision-maker should be willing to pay to reduce
uncertainty through a sample of a certain size and to set this
against the costs of obtaining that sample [130].
VOI analysis is important in situations where a decision-
maker might prefer to postpone making a decision to collect
more information. Basing that decision merely on the outcomes
of sensitivity analyses would lead to suboptimal decision-
making. As suggested by the ISPOR task force on Good Research
Practice in Modeling Studies “The decision to obtain additional
data to inform a model should be based on a balance between the
expected value of the additional information and the cost of the
information.”
Model validation. The ﬁnal part of any model development
should concern validation. Several types of validation may be
distinguished, among which are: face validity, internal validation,
between-model validation, predictive (or prospective) validation,
and external validation [116,131].
Face validity means that the results produced by a model look
valid at ﬁrst inspection. If for example a model for pneumococcal
vaccination results in so many cases of otitis media that every
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child under four would have at least four episodes per year, one
might question this result. Such unexpected results are always
reason to thoroughly check the model and the inputs.
Internal validation concerns the comparison of model outputs
with data used in the model development. While this type of
validation is straightforward if the model is based on one source
of data, it becomes more complicated if the model is based on a
synthesis from various sources of data. It is possible that no
model input can be chosen so that the model validates well
against each separate data source. However, good effort should
at least be made to describe the deviations from the data sources
and possible explanations.
Between-model validation involves comparison of the current
model and published or publicly available models. If the results
differ, an attempt should be made to clarify whether these dis-
crepancies are because of difference in model structure or model
input.
Predictive validation aims to compare model results to newly
available data from the same data source that was used as model
input. On the other hand, external validation concerns the com-
parison of model results to data from studies not used in the
model development. These types of validation are not always
possible; if a model contains all data currently available, there is
no data source for external validation. As the ISPOR task force
on Good Research Practice in Modeling Studies remarks, “. . . it
is not necessary that every data estimate or structural assumption
be tested in prospective studies, in advance of model use.”
However, they also stress that models should never be regarded
as immutable. They should be updated and possible abandoned
as new evidence becomes available to inform structure or input
values. If models are inconsistent with the new evidence but have
not been amended to calibrate against this evidence, the model
should be abandoned until such recalibration has been ﬁnished.
The validation phase of model development should be seen as
important as all other phases. Researchers should document their
validation procedure, and report it in their publications.
How Can We Make the Science Better?
The International Society for Pharmacoeconomics and Outcomes
Research has published best practices document for the design,
conduct, and reporting of economic analyses alongside clinical
trials as well as decision modeling studies [58,116]. Whether
explicit guidelines alone will foster improvements in the quality
of future studies remains a question, given evidence that such
guidelines have had minimal or slow impact in improving the
quality of subsequent studies [3,64,132,133].
Part of this problem may be that most of the advances in the
statistical techniques for analyzing cost data have been published
in highly technical economic or biostatistics journals. Although
some applied researchers may not be reading such literature,
many may have difﬁculty understanding the rationale for and
implementation of these technical methods. There is clear need
for publication in more applied journals that focus on explaining
these technical advances in an easily understandable format to
support knowledge transfer to researchers who need to apply
these newer methods. In addition, there is an equally clear need
for better training and education so that researchers can under-
stand more sophisticated techniques. Another problem in raising
the quality of studies is space. Transparency of a model is of
utmost importance for modeling studies to be taken seriously,
both within the health economics community and among clini-
cians and decision-makers. To achieve full transparency, the
model or detailed model description should be made available in
electronic format, since it is often not possible to describe every
detail of the model sufﬁciently in an article because of space
restrictions.
Additional efforts to improve the quality of future studies
may involve providing tools to peer reviewers for both funding
agencies and journals so as to identify studies that fail to apply
best practices. For example, peer reviewers might be provided
with a clear check list of all requirements. Thus, all studies are
reviewed consistently, hopefully leading to an increased quality.
Regulatory and reimbursement authorities should also explicitly
adopt best practices guidelines and uphold all economic data
submissions to these high standards while making reimburse-
ment decisions.
Journals and Publication Quality
Journal publication plays a critical role in quality improvement
of CER research. This can be done by establishing requirements
and guidelines for the conduct and reporting of the various types
of studies that comprise the ﬁeld, through the peer-review
process, by dissemination of studies, by peer feedback, and as an
ongoing learning process for researchers. Although published
work may include abstracts, posters and podium presentations,
newsletters and other non peer-reviewed publications (such as
educational texts, patient information and marketing materials),
for the purposes of this ﬁrst report the focus has been on peer-
reviewed journal publications because these are most accessible
and easiest to track.
There are a great many journals globally. To determine how
many of these routinely accept and publish articles relevant to
HEOR, and how many of these provide or require guidelines for
the conduct and reporting of these studies, a survey of the World
Association of Medical Editors (WAME; http://www.wame.org)
was carried out. This organization represents more than 965
biomedical journals, from more than 91 countries, from all geo-
graphic regions of the world. As such, WAME was an ideal
source of information relevant to quality improvement in HEOR
publication. In the survey which all WAME members were
invited to participate, they were asked about journal type, loca-
tion, scope, circulation, whether they accepted HEOR articles
and which types of studies, and how they found reviewers for this
type of work. They were also asked whether any HEOR or CER
guidelines were recommended or mandatory for authors or
reviewers, and if so, which ones.
Of the 965 journals represented in WAME, 55 (6%)
responded to the survey. These came from 29 countries and all
continents, with 45% representation for North America and
Europe. Almost all (98%) were peer reviewed, and the majority
(72%) international in readership. Most respondents (83%) were
high-level editorial staff. Journal readerships encompassed clini-
cal and academic health-care researchers (76% of respondents),
health-care decision-makers, health service researchers, and
medical generalists, and specialists (50–67%), health-care poli-
cymakers (40%), and other types of readers (37%) (students,
patients, or the general public, the paramedical professions, other
areas of academia).
The vast majority (92%) of journals accepted all or some
types of HEOR work. Of the 10 categories of HEOR research
published by respondents (Fig. 2), epidemiological burden of
illness studies, database analyses and systematic reviews or meta-
analyses were most commonly reported (77–79%), registry
studies, clinical trials with economic or resource utilization data,
economic burden of illness studies and epidemiological modeling
studies were reported by about half the respondents (46–62%),
and economic modeling, naturalistic clinical trials were least
frequently reported (37–40%).
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Although most journals recommended directly in their
Author Instructions the International Committee of Medical
Journal Editors (ICMJE) requirements (which includes references
to no economic guidelines but some HEOR-relevant guidances
[MOOSE (meta-analysis of observational studies in epidemiol-
ogy), CONSORT (RCTs), STARD (studies of diagnostic accu-
racy), QUORUM (systematic reviews and meta-analyses) and
STROBE (observational epidemiology studies)] or other special-
ized guidances (QUORUM, STROBE, CONSORT, STARD, and
two references for basic statistics), none of the journals provided
their own HEOR guidance, and only 4 of the 54 responding
journals recommended the BMJ health economic study guide-
lines [64]. The Cochrane Web site did, however, have links to
some PRO and HEOR guidances.
About 58% of journals did not provide their reviewers with
any guidelines for evaluating HEOR studies. For the 42% who
said they did, in all cases, these were the same as author guide-
lines (e.g., instructions to authors, ICJME) and only rarely spe-
ciﬁc to HEOR.
Journals were asked if they would consider using a standard
set of HEOR guidances from a recognized professional body to
enhance the quality of published HEOR research in their journal;
91% said they would if these were made available.
When asked about the ease with which they found reviewers
for HEOR articles, 27% of journals had great difﬁculty, 60%
said it was difﬁcult for some types of articles, and 6% had no
difﬁculty. Almost 90% of respondents felt it would be useful if
they had a pool of expertise available to perform reviews of
HEOR for their journal. The areas of expertise speciﬁcally men-
tioned covered the spectrum of HEOR research: policy analysis,
economic outcomes, resource utilization, clinical epidemiology,
public health, preventive medicine, mental health (and other
specialties), statistics, and methodologies.
Although this survey sample size was small, a fairly repre-
sentative range of journals responded and several clear mes-
sages were heard. 1) Many biomedical journals accept and
publish HEOR research; 2) Almost all do so without giving
clear guidance to either authors or reviewers about quality
standards for this type of research so discussion of quality
control at either the article production stage or the peer-review
stage is currently moot. HEOR quality is currently left entirely
up to the skill, knowledge and experience of each author and
reviewer; 3) Most respondents expressed interest in clear guid-
ances to which they could refer; and 4) many of the respon-
dents reported difﬁculty ﬁnding expert reviewers for HEOR,
and almost all were interested in having a larger pool of
reviewers.
Future Plans
First steps in improving the quality of HEOR research in publi-
cations would be to: 1) develop standard guidances to which
journals are able to refer their authors and their reviewers; 2)
lobby to establish these guidances within the ICJME Require-
ments to which most journals refer in their Author Instructions;
3) provide some form of support in terms of additional expertise
to those journals without appropriate reviewers. Finally, 4) it
would be worthwhile to resurvey WAME members to gauge
change over time.
There are also a few research groups who from time to time
perform evaluations of HEOR research quality in the published
literature [4,6,8,134]. It would perhaps be more useful for these
evaluations to use quantitative quality measures that might be
compared across evaluations, and follow the evolution of these
over time. This might be an ISPOR sponsored initiative, or one
undertaken by one or more of the groups currently involved in
such evaluations. Rather than reinventing the wheel, it would be
worthwhile to examine possible quantitative measures already
established, such as the QHES (Quality of Health Economic
Studies) instrument [1,7]. A search for other instruments already
in development is recommended.
Finally, once standardized, quantitative quality measures
have been established, we recommend ongoing assessment of the
quality of published HEOR and its reporting through longitudi-
nal sampling of the literature and other publications, perhaps
with annual or biannual reports.
Types of HEOR studies accepted (% responders)
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Figure 2 Types of Health Economic and Out-
comes Research (HEOR) articles accepted for
publication by journals responding to the QICER
survey.
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Decision-Makers, Practitioners and
Evidence-Based Medicine
The Simplest Scheme Model (SSM)
The process of health care decision-making in the era of
evidence-based medicine (EBM) can be described by the simplest
scheme model (SSM) with three steps:
1. generating evidence by researchers and compiling this evi-
dence in databases;
2. extracting and interpreting evidence from these databases
by decision-makers or EBM practitioners; and
3. applying this evidence in health care settings at local
levels.
The three-step scheme (SSM) is a clue to the barriers to use
and application of cost-effectiveness results faced by decision-
makers and clinical practitioners. The second step might result in
some information loss or inappropriate interpretation, an evi-
dence gap. Since decision-makers rarely access the full range of
evidence from databases, there could be gaps between stored
evidence and that extracted in forms such as partial evidence,
abstracts, conclusions, executive summaries, commentaries,
translations, etc.
In general, practitioners of EBM and decision-makers in
health care tend to regard CER as of limited use, even though it
must be considered for rational resource allocation in health
care. Some obstacles result from insufﬁcient knowledge or skills
in cost-effectiveness analysis. Such insufﬁciencies are related to
the “evidence gap” mentioned above, and may lead to skepticism
about cost-effectiveness research, often bringing decision-makers
to doubt the quality of the studies and the data.
One classic ﬁnding on limitations comes from a study [63]
which surveyed almost 800 UK decision-makers. The authors
concluded that the use of health economic evidence at the local
level was not extensive. The major reasons for such a limited use
were the inﬂexibility of budgets, limiting movement of resources
between primary and secondary care, and the inability to free
resources to adopt new interventions. These issues are related to
the third step in the SSM. It was also reported that decision-
makers were concerned about the credibility of the studies them-
selves, speciﬁcally with respect to large numbers of assumptions
and industry funding. These are validity or credibility issues
associated with the ﬁrst step in the SSM.
Another limitation was reported by a survey [135] which
conducted interviews with 17 pairs of UK NHS decision-makers.
It raised the issue of technical terms employed in pharmaco-
economics. Some of key words in health economic outcomes
research, such as incremental cost-effectiveness ratios, quality-
adjusted life years, and willingness to pay, were either not under-
stood or considered irrelevant by decision-makers surveyed. This
issue is related to an evidence gap at the second step of the SSM.
These studies shed light on key barriers to the use of CER in
health care decision-making: validity, generalizability, and local
level decision-making.
Some of treatments to overcome such limitations observed in
the SSM were investigated by Crump et al. [136] who undertook
interviews with12 medical decision-makers in the UK Leicester-
shire Health Authority, part of the European Network on Meth-
odology and Application of Economic Evaluation Techniques
project [137]. Factors identiﬁed that encouraged decision-makers
to make more use of economic evaluations were: appraisal of
studies by a trusted source; increasing ﬂexibility in health care
budgets; and better explanation of the practical relevance of
study results.
The Evidence and Value: Impact on Decision-Making
(EVIDEM) Model
The EVIDEM [56,57,138–142] model is somewhat more
detailed than SSM. The basic framework from evidence to
decision-maker is similar to that of SSM, but EVIDEM deals with
more sophisticated subprocesses in the decision-making scheme,
which includes:
1. Providing relevant evidence;
2. Assessing evidence for HTA report;
a. Synthesizing evidence with weights; and
b. Quantifying quality of evidence with quality matrix
resulting in scores.
3. Evaluating intrinsic values based on Multicriteria Decision
Analysis with weights and scores; and
4. Evaluating extrinsic values leading to decisions.
Given any intervention setting in health care, the EVIDEM
team clariﬁes the practical framework for decision-making, pro-
vides relevant evidence, supports the deliberative process, and
shares the decisions transparently. One of the advantages for the
EVIDEM model is to bridge health technology assessment and
multi-criteria decision analysis in a transparent and quantiﬁable
approach.
Discussion
As for economic evaluations and decision-making framework,
one study [143] was conducted by drawing on decision-makers
from two UK health authorities, Leicestershire and North York-
shire, employing the National Health Service Economic Evalua-
tion Database (NHS EED) [144] as a research vehicle. It
conﬁrmed that decision-makers generally recognize the useful-
ness and necessity of published cost-effective evidence in inform-
ing their decision-making processes. However, they often
regarded the value of studies limited because of poor generaliz-
ability, narrowness of research questions, and lack of method-
ological rigor, all of which are common seen in published articles.
As reported previously [136], using trusted sources to appraise
studies encouraged decision-makers to use CER studies, as well
as having a quality-scoring system for published studies and not
just the critical summaries from NHS EED.
The same research group [143,145] argued that there could
be two approaches to addressing the problem: changes to the
performance of economic evaluation and changes to the process
of decision-making in the NHS. However, they continue to con-
centrate on one side of the problem, exploring ways to make
economic studies more accessible without losing the key elements
of critical appraisal. Nevertheless, they also state that: 1) it would
be productive to examine some of the potential ﬂaws in health
care decision-making; 2) they share concern about requests for
quality scores which might lead to even less critical assessment of
ﬁndings; and 3) cost-effectiveness analysis makes the shortcom-
ings of the clinical data much more apparent. Regarding the
quality of clinical effectiveness data in economic studies, we need
to ﬁnd out whether the problem is: the lack of good-quality data
for economic evaluations or the lack of available good clinical
data for economic studies performed in time of need. There is
often a problem of a long and inexplicable lag between the
publication of the ﬁrst clinical data and the subsequent publica-
tion of the ﬁrst cost-effectiveness study [146]; it was suggested
that there should be better strategic planning connecting clinical
and economic research plans.
The other study [145] pointed out the general assumption has
been that if decision-makers do not ﬁnd economic evaluations
useful, then the way the evaluations are conducted or presented
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must be changed. Also if an economic decision framework is not
satisfactory for decision-makers, it must be assumed there is a
different and superior model for decision-making. In addition,
they questioned how decisions are made by health authorities for
service planning and resource allocation without substantive eco-
nomic input. To promote better use of cost-effective evidence
among NHS decision-makers, it was suggested:
• changing the process for NHS decision-making;
• changing policies on funding local economic studies and
expertise; and
• using decision-makers with a better grasp of economics.
They insisted that the changes above might be more appropriate
than modifying economic methods to inform unclear decision
process.
In an effort to better understand HEOR researchers and
decision-makers, a Web-based survey was conducted of all
ISPOR members, to which 122 responded. The aim of the survey
was to understand the degree of incorporation of HEOR in
decision-making [147].
Thirty-four percent (n = 42) of respondents identiﬁed them-
selves as a drug, medical device or diagnostic treatment decision-
makers. Years of experience as a decision-maker were
categorized as: less than one year, 1–5 years, 6–10 years, 16–20
years, or greater than 20 years. The majority of respondents had
between one and ﬁve years of experience. Approximately a
quarter of the respondents were members of a Pharmacy &
Therapeutics Committees, and a ﬁfth were practicing pharma-
cists. The majority resided in the US, followed by the United
Kingdom, Germany, Canada, and Japan.
All respondents had read articles containing HE information;
the majority had read articles related to other common terms in
HEOR. Overall, 95% of reported receiving formal training; 90%
had some training in pharmacoeconomics, and only 40% formal
training regarding burden of illness and patient-reported out-
comes. The term training here referred to “formal schooling,
attended courses, worked with an expert or read extensively.”
Ninety-ﬁve percent of decision-makers believed the training
helped them in selecting appropriate interventions, 86% used
some form of HE analysis to make decisions. Cost-effectiveness
and cost-minimization analyses were the most common analyses
used. Seventy-nine percent of respondents had conducted some
type of HE analysis. Again, cost-effectiveness and cost minimi-
zation analyses were the most common. Seventy-ﬁve percent of
decision-makers considered HE and/or outcomes research in
their last intervention decision.
In reaching out to decision-makers and practitioners, a
sophisticated decision-making model such as EVIDEM should be
considered. An advantage of the EVIDEM model is its inner
structure that separates intrinsic and extrinsic values.
Recommendations
To recognize true value of CER and to establish evidence-based
decisions, the QICER task force recommends that ISPOR imple-
ment the following:
• Promote comparative effectiveness and outcomes research
to generate evidence hierarchy;
• Develop, validate, and revise a decision-making model to ﬁll
the gap between health care researchers and practitioners
(or decision-makers) associated with the concept of con-
tinuous quality improvement;
• Establish the science, from generating evidence to making an
evidence-based policy, taking into account how to integrate
intrinsic and extrinsic values with multi-criteria decisions;
• Provide the right information at the right time in health care
delivery;
• Translate clinical research into clinical decisions and
actions; and
• Promote communications with practitioners and decision-
makers who are faced with the challenges as how to better
understand complex socioeconomic evaluations, how to
improve the decisions, and how to seek the rationality of
reasoning.
QICER Final Report Recommendations
The QICER Task Force recommends that ISPOR implement the
following:
Guidelines
• Promote harmonization of CER guidelines, allowing for
differences in application, regional needs and politics;
• Evaluate available instruments or promote development of
one to quantify the impact of CER guidelines on the quality
of CER studies;
• Report periodically on available guidelines;
• Evaluate periodically the quality of studies submitted to
decision-making bodies (as public transparency increases)
and journals (preferably with standardized CER guidelines);
and
• Develop trainings for researchers and others using CER
guidelines, and promote effective mechanisms of continu-
ous knowledge transfer.
Methodologies
• Promote publication of methodological guidelines in more
applied journals in more easily understandable format to
transfer knowledge to researchers who need to apply more
rigorous methods;
• Promote full availability of models in electronic format to
combat space restrictions in hardcopy publications;
• Promote consistency of methodological review for all CER
studies;
• Promote adoption of explicit best practices guidelines
among regulatory and reimbursement authorities;
• Periodically update all ISPOR Task Force reports;
• Periodically review use of ISPOR Task Force guidelines and
their impact on CER quality; and
• Periodically report on statistical and methodological chal-
lenges in CER.
Publications
• Develop standard HEOR conduct and reporting guidance
(beginning with CER) to which journals may refer their
authors and their reviewers;
• Lobby to establish these guidances within the ICMJE
Requirements to which most journals refer in their Author
Instructions;
• Provide support in terms of additional reviewer expertise to
those journals without appropriate reviewers;
• Periodically report on journals publishing CER; and
• Periodically report on the quality of CER publications.
Decision-making
• Recognize those countries/agencies/practitioners/ private
companies using CER well at least annually;
• Recognize those practitioners/researchers supporting patient
use of CER in decision-making at least annually; and
• Promote frequent presentation of case studies of the applied
use of CER concepts or guidelines.
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